MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that ...
Le Lézard

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced its business update and financial results for the first nine months of 2025. "This quarter highlights ...